Biomotion Sciences Ordinary Shares (NASDAQ:SLXN) — Market Cap & Net Worth
Market Cap & Net Worth: Biomotion Sciences Ordinary Shares (SLXN)
Biomotion Sciences Ordinary Shares (NASDAQ:SLXN) has a market capitalization of $1.94 Million ($1.94 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30136 globally and #6130 in its home market, demonstrating a 9.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomotion Sciences Ordinary Shares's stock price $0.39 by its total outstanding shares 5560256 (5.56 Million). Also see SLXN asset base for a full breakdown of the balance sheet.
Biomotion Sciences Ordinary Shares Market Cap History: 2021 to 2026
Biomotion Sciences Ordinary Shares's market capitalization history from 2021 to 2026. Data shows change from $53.82 Million to $2.14 Million (-45.04% CAGR). Also see SLXN cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Biomotion Sciences Ordinary Shares is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #882 of 976 |
Weight: Biomotion Sciences Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biomotion Sciences Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomotion Sciences Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Biomotion Sciences Ordinary Shares stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SLXN by Market Capitalization
Companies near Biomotion Sciences Ordinary Shares in the global market cap rankings as of September 18, 2026. Review SLXN goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biomotion Sciences Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Biomotion Sciences Ordinary Shares Historical Marketcap From 2021 to 2026
Between 2021 and today, Biomotion Sciences Ordinary Shares's market cap moved from $53.82 Million to $ 2.14 Million, with a yearly change of -45.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.14 Million | -79.95% |
| 2025 | $10.68 Million | -4.48% |
| 2024 | $11.18 Million | -81.47% |
| 2023 | $60.33 Million | +7.75% |
| 2022 | $55.99 Million | +4.03% |
| 2021 | $53.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Biomotion Sciences Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.94 Million USD |
| MoneyControl | $1.94 Million USD |
| MarketWatch | $1.94 Million USD |
| marketcap.company | $1.94 Million USD |
| Reuters | $1.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more